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Abstract 
The renewed interest in donation after cardio-circu-
latory death (DCD) started in the 1990s following the 
limited success of the transplant community to expand 
the donation after brain-death (DBD) organ supply and 
following the request of potential DCD families. Since 
then, DCD organ procurement and transplantation 
activities have rapidly expanded, particularly for non-
vital organs, like kidneys. In liver transplantation (LT), 
DCD donors are a valuable organ source that helps to 
decrease the mortality rate on the waiting lists and to 
increase the availability of organs for transplantation 
despite a higher risk of early graft dysfunction, more 
frequent vascular and ischemia-type biliary lesions, 
higher rates of re-listing and re-transplantation and 
lower graft survival, which are obviously due to the 
inevitable warm ischemia occurring during the declara-
tion of death and organ retrieval process. Experimental 
strategies intervening in both donors and recipients at 
different phases of the transplantation process have 
focused on the attenuation of ischemia-reperfusion in-
jury and already gained encouraging results, and some 
of them have found their way from pre-clinical success 
into clinical reality. The future of DCD-LT is promising. 
Concerted efforts should concentrate on the identifica-
tion of suitable donors (probably Maastricht category 
Ⅲ DCD donors), better donor and recipient matching 
(high risk donors to low risk recipients), use of ad-
vanced organ preservation techniques (oxygenated hy-
pothermic machine perfusion, normothermic machine 
perfusion, venous systemic oxygen persufflation), and 
pharmacological modulation (probably a multi-factorial 
biologic modulation strategy) so that DCD liver al-
lografts could be safely utilized and attain equivalent 
results as DBD-LT.  
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INTRODUCTION 
The first human liver transplantations (LT) were per-
formed from donation after cardio-circulatory death 
(DCD) in the 1960s[1-4]. DCD-LT was nonetheless almost 
universally abandoned in the following two decades, 
given the well-recognized Harvard brain-dead concept in 
1968 and given the better results of  LT originating from 
donation after brain death (DBD)[5]. In 1983, LT was ap-
proved as a therapeutic modality for end-stage liver dis-
eases after a long period considered as an experimental 
procedure. The renewed interest in DCD donors started 
in the 1990s following the limited success of  the trans-
plant community to expand the DBD organ supply and 
following the request of  potential DCD families.  
If  DCD kidneys are increasingly accepted around the 
world[6], the use of  DCD livers remains limited in expe-
rienced transplant centers due to higher risks of  primary 
graft dysfunction and biliary complications as well as a 
lack of  a reliable viability testing prior to liver implanta-
tion. However the number of  DCD-LT increased rap-
idly over the past decade. In the United States, 276 DCD 
liver transplants were performed in 2008 compared to 
only 23 cases in 1999, making up 5% of  the deceased 
donor (DD) liver transplants[7-10]. The same trend was 
observed in the United Kingdom[11-13], Spain[14], Neth-
erlands[15] and Belgium[15,16]. Netherlands had the high-
est rate of  DCD- over DD-LT in the world (22.5% in 
2008)[15]. France has just initiated its DCD-LT program 
since 2010[17]. In Japan, although DCD donors were the 
essential DD source, its use was reserved mainly for 
kidney, pancreas and islet transplantation[18]. Using a 
mathematical model to analyze the potential impact of  a 
DCD policy on LT programs, Chaib reported if  1%, 5% 
and 10% of  deceased individuals became DCD donors, 
there would be 8%, 27% and 37% relative reductions in 
the size of  waiting list, respectively[19]. The use of  DCD 
livers could increase the supply of  transplants by 53%[20]. 
Centers with active DCD-LT programs usually reported 
4%-10% rates of  LT from the DCD source[21]. The po-
tential impact of  DCD use on the DBD availability is 
also a controversial issue. Controlled DCD programs 
might negatively influenced DBD activity in Belgium, 
Netherlands and United Kingdom while uncontrolled 
DCD donors seemed to be a clear additional source of  
organs for transplantation in France and Spain[22].  
Most countries use Maastricht-category-3 DCD do-
nors for LT, except France and Spain, where categories 
1 and 2 are exclusively used due to legal interdiction of  
discontinuation of  therapy in irreversibly brain-injured 
individuals[17,23,24]. German law prohibits any DCD organ 
procurement and transplant activity. In Italy, death of  
a human being must be declared 20 min after cardiac 
arrest using continuous electrocardiography. The pro-
cedure therefore will enable, at best, retrieval of  only a 
few marginal kidneys and some tissues, and will not be 
helpful for patients on LT waiting lists[25]. This article is 
aimed at reviewing mono- and multi-centric DCD-LT 
outcomes, experimental strategies on animal models to 
optimize the utilization of  this donor source and its fu-
ture development.  
 
DIFFERENCES BETWEEN DCD AND DBD 
DONORS PERTINENT TO LT OUTCOMES  
Generally results of  DCD-LT are inferior to those from 
DBD-LT with regard to both short-and long-term graft 
and patient survival as well as post-transplant morbid-
ity. Expected DCD-LT outcomes could be explained by 
inherent differences between DCD and DBD donors in 
circumstances of  death, warm ischemia time (WIT) and 
donor cause of  death. Consequently, a different strategy 
of  DCD use in terms of  logistics of  organ retrieval and 
preservation, allocation and recipient selection appears 
necessary to guarantee acceptable results. These differ-
ences will be briefly discussed prior to considering re-
sults of  DCD-LT in detail. 
Circumstances of death and consequent warm ischemia 
time 
In DCD, donor death is diagnosed on the basis of  irre-
versible cessation of  cardio-pulmonary function instead 
of  conventional neurologic criteria. As a result, organs 
from DCD donors are subjected to a period of  hypoten-
sion, hypoxia and acirculation prior to organ procure-
ment and this WIT adversely affects tissue viability and 
graft function after transplantation[26]. An international 
classification of  DCD donors into 4 categories was first 
proposed in 1995 and widely accepted up to now[27]. 
New DCD categories have been recently suggested in 
Spain[28,29], Italy[30] and Belgium[31]. The length of  WIT 
varies greatly according to the type of  DCD process. It 
is longest among uncontrolled category -1 and -2 (usually 
90-120 min) and shorter among controlled category -3 
and -4 DCD donors (usually 20-30 min). In brain death, 
issues related to donor warm ischemia are eliminated be-
cause DBD donors have an effective natural organ per-
fusion and a potentially well-preserved organ function 
and WIT is thus nearly equal to zero. 
However, WIT is heterogeneously defined among 
authors[32]. In the controlled DCD context, the common-
est definition is the time interval between withdrawal 
of  both ventilator and cardiac support to start of  cold 
flushing of  the organ[33,34]. This definition includes the 
no-touch period and the time of  death declaration and is 
proposed to have two phases (withdrawal and acircula-
tory phases). Other authors used a blood pressure (BP) 
or oxygen saturation threshold below which would be 
defined as the beginning of  true WIT (systolic or mean 
BP < 35-60 mmHg, oxygen saturation < 25%-70% or 
unreadable)[35-42]. de Vera et al[34] did not use a BP thresh-
old to define the start of  WIT because tissues are still 
hypoxic in a DCD donor who maintains a BP but has 
ceased to ventilate. It is unknown at what BP or oxygen 
saturation the liver parenchyma and biliary system under-
go irrecoverable injury[43]. The first international Non-
Heart Beating Donor workshop in Maastricht in 1995 
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suggested WIT should be calculated from the moment 
of  cardiac arrest until the start of  hypothermic flush-
out[44]. This definition may be useful for consistency but 
is inaccurate at the cellular level. Hypoxia starts when 
the blood flow or oxygenation no longer meets cellular 
metabolic needs[37]. The start of  WIT may be chosen 
prior to asystole, and the end of  WIT may be at or after 
aortic flushing[45]. Apparently a well-accepted definition 
of  donor organ ischemic times is needed to standardize 
nomenclature and allow accurate comparisons of  indi-
vidual DCD studies[46,47] (Figure 1).  
In transplant practice, WIT should be minimized as 
much as possible. For controlled DCD donors, the pos-
sibility to predict whether a potential donor will or will 
not expire in a time frame consistent with donation is 
extremely important, because prolonged time to asystole, 
likely resulting in suboptimal organ perfusion, is a com-
mon reason for non procurement of  DCD grafts[48,49]. 
Time between therapy withdrawal and cardiac arrest usu-
ally does not exceed 1 h in most DCD donors. However, 
if  a DCD donor has a period of  relatively hemodynamic 
stability after life-support withdrawal, this period may be 
extended beyond 1 h without additional warm injury to 
the organs[50]. Some authors emphasized during the with-
drawal phase, time to a systolic BP < 50 mmHg should 
be < 30 min[20] and the hypotensive period (mean BP 
< 50 mmHg) < 15 min[51]. Manara et al[52] proposed the 
so-called functional WIT, which is measured from the 
donor’s systolic BP < 50 mmHg, the arterial oxygen sat-
uration < 70%, or both, to the start of  cold perfusion, 
should not exceed 30 min and may be limited to 20 min 
in suboptimal donors. Several factors have been identi-
fied as predictors of  rapid death following treatment 
withdrawal and include the DCD tool of  University of  
Wisconsin[53], donor Glasgow coma scale, inotropic use, 
BP at treatment discontinuation, high FiO2 and mode of  
ventilation[54,55]. Withdrawal of  therapy is preferably oc-
curred in the operating room with a donor surgical team 
immediately available. Prior to cessation of  the ventilator 
and organ perfusion support, the donor may be already 
prepared and draped, and the surgical instruments, pres-
ervation solution and tubing are set up to facilitate rapid 
organ recovery. The super rapid recovery technique is 
preferable and organs may be removed en bloc[39,50]. For 
uncontrolled donors, in vivo organ preservation tech-
niques, like in-situ intravascular cooling using a double 
balloon and triple lumen catheter or hypo- and normo-
thermic cardiopulmonary bypass with extracorporeal 
membrane oxygenation (ECMO), should be employed. 
With regard to the logistic organization, two frequently 
mentioned initiatives are the “Maastricht’s box” and the 
“Madrid’s rapid identification and response system”[6]. 
Donor cause of death 
DCD donors do not experience the brain dead process. 
Brain death provokes a cascade of  changes in hemo-
dynamics, hormones, and immune response, which 
negatively affect donor organ viability and transplant 
outcomes[56,57]. Hemodynamic instability may have del-
eterious effects on liver function, although the liver has a 
high tolerance to marked hypotension and a large physi-
ological reserve. Only a few histological changes were 
observed in the liver both on light and electron micro-
scopic examination during the brain dead process[58,59]. 
The most important changes are the increased liver 
immunogenicity with subsequent increased host allo-
responsiveness and the occurrence of  apoptosis of  he-
patocytes[60]. Clinical findings in livers from DBD donors 
revealed significantly higher leukocyte infiltrates, up-
regulation of  adhesion molecules [intercellular adhesion 
molecule (ICAM), vascular cell adhesion molecule] and 
pro-inflammatory cytokines [interleukin-6 (IL-6), IL-10, 
IL-1β, interferon γ and tumor necrosis factor-alpha 
(TNF-α)], along with an increased expression of  major 
histo-compatibility complex-Ⅱ relative to livers from 
living donors[61,62]. The peak time of  cytokine expres-
sion and cell infiltration is during brain death and organ 
procurement but not after reperfusion[61]. These changes 
may amplify ischemia-reperfusion injury (IRI) during the 
transplant procedure and accelerate graft rejection after 
transplant[63]. In reality, donor brain-death mechanisms 
are quite varied and large differences may exist in the de-
gree of  impaired organ quality and transplant outcomes. 
The impact of  donor cause of  death on transplant out-
comes has been recently confirmed in a United Network 
for Organ Sharing (UNOS) registry analysis, in which 
the cerebro-vascular accident presented as a predictor 
of  worse graft survival across all organs relative to other 
donor modes of  death[64].   
Uncontrolled DCD donors whose cause of  death is 
usually other than neurologic do not undergo the pro-
cess of  brain death, while most controlled DCD donors 
have sustained irreversible cerebral injuries. As a result, 
organs from controlled DCD donors are likely to suffer 
more from the harmful immunologic and inflammatory 
effects of  acute brain injury than those from uncon-
trolled DCD donors[65].  
Allocation policy 
It is reported that organs that have already subjected to 
warm ischemic injury have an increased susceptibility to 
damage during cold storage[66]. The incidence of  primary 
non-function (PNF) was 2.5 times less in patients with 
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Therapy withdrawal Cardiac arrest Cold perfusion 
Agonal phase Acirculatory phase 
Total WIT
True WIT
Systolic or mean BP < 35-60 mmHg
Arterial oxygen saturation < 25%-70%
t
Figure 1  Different ways of warm ischemia time definition in the controlled 
donation after cardio-circulatory death setting (see text for more details). 
True warm ischemia time (WIT) is also called complete or functional WIT; Total 
WIT is also called overall WIT; Agonal phase is also called withdrawal phase. 
BP: Blood pressure; t: Time.
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cold ischemia time (CIT) ≤ 8 h vs those with CIT > 8 h 
(5% vs 13%)[34]. The incidence of  graft failure within 60 d 
of  transplantation was 10.8% if  CIT < 8 h and substan-
tially increased to 30.4% and 58.3% if  CIT > 8 h and > 
12 h, respectively[67]. Proper and rapid allocation of  DCD 
livers thus appears pivotal to minimize CIT. One-year 
graft survival of  DCD livers shared regionally was less 
good than those shared locally (67% vs 77%)[68] and the 
relative risk of  graft failure from nationally shared DCD 
livers was 31% higher than locally or regionally shared 
ones[69]. Thus a policy to favor local use of  DCD livers 
seems reasonable[67,68]. However, parallel (backup) offers 
should also be made to expedite organ placement[33]. The 
exchange of  DCD livers between transplant centers has 
been successfully done but requires a more efficient and 
rapid referral system due to a lower tolerance of  these al-
lografts to cold storage[70].  
Regarding recipient selection criteria, DCD livers 
could be routinely discussed and offered to all recipi-
ents on the waiting list[20,70,71] or selectively reserved to 
uncomplicated cases to ensure short CIT (by avoiding 
cases with extensive history of  abdominal surgery or 
portal-vein thrombosis)[20,35]. An expected long surgi-
cal procedure exceeding 8 h of  CIT, logistical reasons 
for an extended CIT, combined organ transplantation, 
recipients with high Model for End-Stage Liver Disease 
(MELD) scores or a large age difference between donors 
and recipients could all result in the refusal of  a DCD 
liver[51]. Patients with stable cholestatic liver disease or re-
transplantation were also excluded from DCD programs 
because of  problems related to the quality of  life in 
primary biliary cirrhosis and to the fear that pre-existent 
warm ischemic biliary damage could trigger the recur-
rence of  primary sclerosing cholangitis[72]. Using DCD 
livers in re-transplanted patients might increase the CIT 
associated with a difficult hepatectomy. Recently LaMat-
tina has demonstrated the feasibility of  simultaneous 
liver and kidney (SLK) transplantation using DCD do-
nors and shown short-term results comparable to those 
of  SLK transplantation using DBD donors, making it a 
valid approach to safely expanding the donor organ pool 
for patients with end-stage liver and kidney disease[73]. 
It is still controversial whether it is better to trans-
plant such grafts into healthy or sicker recipients (i.e., 
according to the recipient liver disease severity). UNOS 
database reviews advocated utilizing DCD livers in “low-
risk” recipients[32,67,74]. de Vera et al[34] also observed better 
graft survival when DCD livers were utilized in patients 
with MELD scores ≤ 30, but simultaneously could 
demonstrate that “sicker”, high-risk recipients (at MELD 
scores > 30 or on organ-perfusion support, like mechan-
ic ventilation or hemodialysis) had a greater patient and 
graft survival benefit from the transplantation of  DCD 
livers compared to patients who are not as critically ill. 
Risk classification for DCD donors and DCD-LT recipi-
ents is summarized in Table 1. Other groups of  patients 
that may have a true survival benefit from DCD-LT in-
clude MELD “disadvantaged” patients (hepato-cellular 
carcinoma patients beyond the Milan criteria or who are 
listed in areas with long waiting times, patients with low 
MELD scores that do not adequately reflect their level 
of  illness and their critical need for a transplant)[34,72].  
Studies about the effect of  DCD liver grafts on 
hepatitis-C virus positive (HCV+) recipients transplant 
outcomes were inconsistent. Nguyen et al[45] and recently 
Hernandez-Alejandro et al[75] found a negative effect of  
HCV on DCD livers, but a formal contraindication for 
the use of  DCD liver allografts in HCV+ recipients 
was not justified except for older donors. In fact, while 
single-center series reported no significant difference 
in graft and patient survival rates of  HCV+ recipients 
and graft loss from HCV recurrence between DCD and 
DBD groups[20,34,76,77], as well as no deleterious effects of  
DCD liver grafts on the disease progression (fibrosis) 
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  Authors                       Donors                      Recipients
  Mateo et al[74] Low risk Both WIT ≤ 30 min and CIT ≤ 10 h RCRR ≤ 1.5 
High risk WIT > 30 min and/or CIT > 10 h RCRR > 1.5
Re-transplantation and/or 
On life-support and/or 
A combination of  ≥ 3 risk factors:  
   Hospitalization or in an intensive care unit
   Serum creatinine > 2 mg/dL
   On dialysis 
   Age > 60 yr
  Lee et al[32] Low risk Donors with no identified donor risk factors Recipients with no identified recipient risk factors
High risk Donors with at least one identified donor risk factor: Recipients with at least one identified recipient risk factor: 
   Donor age > 45 yr    Previous transplantation
   WIT > 15 min    Life support at transplantation
   CIT > 10 h
  de Vera et al[34] Low risk                             - MELD scores ≤ 30
High risk                             - MELD scores > 30
On life support (mechanical ventilation, hemodialysis)
Table 1  Risk classification for donation after cardio-circulatory death donors and donation after cardio-circulatory death-liver trans-
plantations recipients
RCRR: Recipient cumulative relative risk; WIT: Warm ischemia time; CIT: Cold ischemic time; MELD: Model for end-stage liver disease.
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in comparison with DBD liver grafts in HCV+ recipi-
ents[77], the most recent UNOS registry data showed 
inferior graft survival but similar patient survival of  
HCV+ recipients with DCD donors compared to ones 
with DBD donors. Furthermore, DCD livers on HCV 
disease do not fare worse than DCD livers on non-
HCV disease. DCD livers thus appeared to be important 
source of  LT for HCV patients[78]. Split livers from DCD 
donors have also been reported in recent years with ac-
ceptable results[79,80].  
 
TRANSPLANT OUTCOMES  
Currently one-year patient survival after DBD-LT and 
to a certain extent after controlled DCD-LT is about 
85%-90% in comparison to 60% in the early eighties and 
around 30% in the early d of  LT and at 5 years post-
transplant patient survival rate remains over 70%. Medi-
cal progress over the past 40 years in the field of  organ 
preservation, surgical techniques, immunosuppressive 
drugs, treatment of  post-transplant complications and 
organ allocation has permitted DCD to become reality 
in the modern era. Although there are concerns about 
the quality of  such organs, with evidence that a pro-
longed WIT causes a raised incidence of  PNF and bili-
ary complications as well as suboptimal graft and patient 
survival when compared to DBD livers, DCD livers 
may be life-saving for those who would die waiting for 
a DBD liver[68] and do increase the number of  organs 
available for LT. With careful donor/recipient selection 
and matching, minimization of  ischemia and good post-
operative care, acceptable results can be achieved. Es-
sential results of  most important publications in the last 
decade in DCD-LT are presented in Tables 2-4.  
Primary non-function 
PNF is usually defined as unrecoverable hepato-cellular 
dysfunction leading to patient death or re-transplantation 
within the first week post-transplant after excluding other 
causes of  graft failure such as vascular thrombosis, bili-
ary complications, rejection or recurrent disease[81-84]. 
Initial studies using uncontrolled DCD donors reported 
a rate of  PNF as high as 50%[85]. Currently only a few 
transplant centers in the world (like Spain, France) used 
this kind of  donors because of  aforementioned reasons. 
By using different in vivo organ preservation methods 
to maintain DCD donors and by strictly applying do-
nor selection criteria, authors in Madrid[71], Barcelona[29] 
and La Coruña[86-89] could obtain promising results from 
Maastricht category Ⅰ and Ⅱ donors with a PNF rate 
of  10%-25%. The discard rate nevertheless was high up 
to 50%-75%[29,71]. In controlled DCD donors, the PNF 
rates are 0% to 12%. Matched analysis[34,72] and registry 
data[67,68] showed a higher rate of  PNF in controlled DCD 
than DBD donors, although no difference was found in 
most comparative studies[20,43,90,91] except one[92]. The in-
creased risk of  PNF in DCD-LT recipients was also con-
firmed in a recent meta-analysis (odds ratio = 3.6, 95% 
CI: 2.1-6.4)[93]. Case-series reports of  controlled DCD-LT 
also had a rate of  PNF between 0% and 10%[42,70,94-97].  
PNF is the consequence of  severe IRI with the initial 
period of  warm ischemia playing a crucial role. Experi-
mental evidence supported that donor WIT should be 
less than 30 min to minimize PNF[98]. This warm ischemia 
(WI) period increases graft susceptibility to damage dur-
ing cold preservation and CIT was a main contributing 
factor to PNF[34,67]; therefore, both periods of  ischemia 
must be kept to a minimum. Many laboratory tests have 
been developed both in animal models and in human 
to predict the probability of  occurrence of  PNF post-
transplant, but none is yet clinically efficient[99]. Recently 
Dahaba proposed bispectral index monitoring as an early 
intra-operative indicator of  early graft dysfunction[100].  
Biliary complications 
Since the introduction of  LT up to now, biliary compli-
cations are always regarded as the “Achilles heel” and 
a major cause of  morbidity and graft failure in patients 
after LT[101]. The most common biliary complications 
are bile leakage and bile duct stricture[102,103]. Strictures 
involving the donor bile duct (> 1 cm above the biliary 
anastomosis) and requiring endoscopic or radiological 
dilatation/stenting or surgery in the face of  a patent, 
non-stenotic hepatic artery was referred to as ischemic-
type biliary lesions (ITBL), based on the radiologic 
resemblance of  those occurring after hepatic artery 
thrombosis (HAT)[51,91,103].  
Abt et al[104] first mentioned the significantly higher 
incidences of  overall biliary complications as well as 
ITBL in DCD-LT recipients, the finding which was 
later confirmed in both matched[34,72] and compara-
tive[20,43,51,89,91,104] studies except series of  Fujita et al[105] and 
Manzarbeitia et al[106]. The rates of  overall biliary com-
plications and ITBL were 10.5%- 53% and 8.3%-38%, 
respectively in DCD-LT compared to 8.3%-22% and 
0%-8%, respectively in DBD-LT. Especially Jimenez-
Galanes reported only a 5% incidence of  ITBL in their 
patients receiving livers from uncontrolled DCD donors 
under normothermic ECMO[71]. A recent meta-analysis 
revealed that DCD recipients had a 2.4 times increased 
odds of  biliary complications (95% CI: 1.8-3.4) and a 
10.8 times increased odds of  ITBL (95% CI: 4.8-24.2) vs 
DBD recipients. In average, biliary complications were 
present in 29% of  DCD compared with 17% of  DBD 
recipients and ITBL in 16% of  DCD vs 3% of  DBD re-
cipients[93]. 
Furthermore DCD recipients who developed ITBL 
experienced a fairly rapid clinical deterioration, charac-
terized by a relatively short mean time from transplant 
to first endoscopic retrograde percutaneous cholangio-
pancreatography (ERCP), from first ERCP to relisting 
and from relisting to re-transplantation (within 180 d)[36,69]. 
ITBL results in re-operation, multiple endoscopic and 
percutaneous biliary interventions, re-transplantation 
and even patient death with markedly increased medical 
care costs[107]. The relative risk (RR) of  developing graft 
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Le Dinh H et al . DCD liver transplantation
Graft and patient survival 
Graft survival is defined as the time from transplantation 
to either re-transplantation or patient death, with “early” 
and “late” graft failure occurring within and beyond 1 
year post-transplant, respectively[34]. Few studies reported 
experience with LT from uncontrolled DCD donors. 
Early results were poor with a PNF rate of  50% and 
one-year graft survival rate of  only 17%[85] leading to a 
scarce usage of  this donor category in the United States. 
Subsequent series in Spain using advanced in vivo organ 
preservation methods showed promising outcomes 
with one- and five-year graft survival rates of  50%-80% 
and 49%, and one- and five-year patient survival rates 
of  70%-85.5% and 62%, respectively[29,71,89]. LT from 
controlled DCD donors offered better results although 
they still appeared inferior to DBD-LT in matched 
studies[34,72], registry data analysis[32,67-69,74,125] and in some 
comparative studies[36,91,92]. One-, three-, five- and ten-
year graft survival rates were 54%-79.5%, 53%-74.5%, 
37.5%-71% and 37.5%-44%, respectively. Patient surviv-
al rates at corresponding time points were 61.9%-91.5%, 
62.8%-89.5%, 42.9%-89.5% and 42.9%-57%, respective-
ly. Transplant outcomes comparable to those obtained 
from DBD-LT have been sporadically reported in select 
centers through careful donor selection and optimization 
of  CIT or through invasive techniques designed to opti-
mize recovery before declaration of  death[20,43,51,104].  
Significant risk factors for DCD liver graft loss have 
been identified by multivariate Cox regression technique 
in both single center studies and large data registry analy-
sis[32,67-69,74,126,127]. Among donor risk factors, age > 50 
years, total WIT > 30-35 min, CIT > 6 h, body weight > 
100 kg and regional or national liver distribution had dele-
terious effects on graft survival[32,74,127]. There is a stepwise 
increase in the relative risk of  graft failure among donor 
age, WIT and CIT[32,127]. Strong recipient determinants of  
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irrigation of  the donor bile duct and pressure perfusion 
of  the hepatic artery during organ retrieval and/or at 
back table[113,118,119], early porto-caval shunt to reduce por-
tal hypertension in the recipient, choice of  reperfusion 
techniques (concomitant vs sequential reperfusion of  
portal vein and hepatic artery)[120] and certainly the most 
important thing is always minimizing warm and cold 
ischemia period[121]. 
   
HAT and stenosis   
HAT is a thrombo-embolic occlusion of  the hepatic 
artery that can occur early or late after LT. Most authors 
used the first 30 d post-transplant as a time point to 
distinguish between early and late HAT[122]. Early HAT 
results in fulminant hepatic failure, bile duct necrosis 
and leaks, relapsing bacteremia and ultimately graft loss 
and recipient death. The frequencies of  early HAT after 
DCD-LT varied from 0% to 16.6% and did not seem 
significantly higher than those after DBD-LT in most 
studies[20,29,34,36,43,51,71,72,89,91,104,105] except Yamamoto et al[90] 
(33.3% vs 0%). Risk factors for early HAT have been 
well analyzed in a recent systemic review[123]. Few de-
tailed studies discussed late HAT. 
The incidence of  hepatic artery stenosis (HAS) was 
not consistently found higher in DCD than DBD grafts 
(12.8%-16.6% vs 0%-5.4%)[72,91]. It is possible that he-
patic arteries are susceptible to WI during DCD organ 
retrieval, resulting in subsequent scar and stenosis. More-
over the increased susceptibility of  DCD livers to post-
operative arterial ischemia might be responsible for more 
biliary strictures in DCD than DBD recipients with HAS 
(83% vs 37%) as well as shorter time to the development 
of  biliary strictures after HAS in the DCD group[91]. In-
adequate surgical technique, vascular trauma by clamps, 
graft rejection, recurrent hepatic disease might also play 
a role in the mechanisms for HAS[72,124].  
  Authors and 
  study period Publication year
Patient number and 
Maastricht category WIT (min) CIT (h) PNF (%) Retransplantation (%)
Graft survival % Patient survival %
1 yr 3 yr 5 yr 1 yr 3 yr 5 yr
  Abt et al[67]
  1993-2001
2004            144 DCD 12.7 8.1 11.81  13.91   70.21   63.31 -   79.7   72.1 -
      26 856 DBD 8.9   6.41    8.31   80.41   72.11   85   77.4
  Mateo et al[74]
  1996-2003
2006            367 DCD 15.6 8.3 - -   711   601   531 - - -
      33 111 DBD 8.4   801   721   651
  Lee et al[32]
  1996-2006
2006            874 DCD 15.4 7.9 - -   72.11   61.81   38.81   82.31   75.91 65.31
      43 734 DBD 8.2   80.71   71.91   65.61   85.41   77.51 71.51
  Doshi et al[68]
  1998-2004
2007            345 DCD - 8.2   6.41  13.01   75   65 -   83   77 -
      20 289 young-DBD 8.1   3.91    5.61   831   751   881   801
         3604 old-DBD 8.2   5.31   76   64   83   73
  Merion et al[125]
  2000-2004
2006            472 DCD - 7.9 - -   70.11   60.51 - - - -
      23 598 DBD 8.1   831   751
  Selck et al[69]
  2002-2007
2008            855 DCD - - -  21.61   73.81   57.61 - - - -
      21 089 DBD    8.81   84.41   74.41
  Mathur et al[127]
  2001-2009
2010          1567 DCD 16.1 7.5 - 13.6 - - -   78   64.9 -
Table 4  Results of donation after cardio-circulatory death-liver transplantations in United Network for Organ Sharing data base registry
DCD: Donors after cardiac death; DBD: Donors after brain death; WIT: Warm ischemia time; CIT: Cold ischemia time; PNF: Primary non-function. Major 
symptomatic biliary complications include biliary leak, anastomotic and non-anastomotic stenosis. 1Numbers denote the statistically significant difference 
between groups.
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graft failure include age > 55 years, history of  previous 
transplantation, medical status at transplantation [intensive 
care unit (ICU) or non-ICU hospitalization, life support, 
dialysis, renal insufficiency], high MELD score (> 30) and 
positive HCV serology[32,74,127]. In the DBD-LT model, it 
has been shown that a single risk factor lessened outcome 
marginally, however, the additive effect of  multiple risk 
factors in a given donor-recipient pair were disastrous[83]. 
Grafts with ≥ 3 donor risk factors had significantly lower 
1-year post-transplant survival than no or only 1 or 2 risk 
factors (58.3% vs 72.6%, 69.2% and 73.9%, respectively). 
No grafts with 4 risk factors survived within 1 year[128]. 
The relative risk of  allograft failure from LT utilizing 
DCD donors was 31%-87% higher than LT utilizing 
DBD donors[67-69,125,126]. Causes of  early graft failure in-
cluded PNF, biliary complications, HAT and deaths from 
sepsis/multi-organ failure. Late graft failure was often 
secondary to chronic rejection and recipient death with a 
functioning graft. 
Although DCD livers may not be as good as DBD 
ones with potential inferior transplant outcomes, there 
are subgroups of  grafts and recipients that could give 
favorable results through appropriate graft and recipient 
matching. Low-risk DCD grafts which are transplanted in 
low-risk patients lead to comparable graft survival rates 
with DBD livers. Livers from DCD donors transplanted 
into high-risk recipients fared poorly independent of  the 
allograft quality[74]. Doshi et al[68] showed DCD liver grafts 
were not inferior to DBD livers from older donors (≥ 60 
years). Given the ever increasing demand for LT, DCD 
livers appear to be a reasonable alternative to increasing 
use of  older or split livers and are a reasonable option 
when death is imminent[68]. Even if  graft or/and patient 
survival is lower with a DCD liver, it is still better than 
dying because of  turning down a DCD offer and con-
tinuing to wait for a DBD liver on these d as the patient’
s choice is frequently not between marginal livers (includ-
ing DCD) and standard livers but between marginal liv-
ers and no livers[105]. The benefit of  earlier access to LT 
provided by a DCD graft could outweigh the risks of  
prolonged waiting for a standard graft[77].  
Re-transplantation 
DCD recipients more often require re-transplantation. Re-
spectively, 21.6%-42% vs 8.8%-16% of  DCD and DBD 
recipients were listed for re-transplantation[36,69]. The re-
transplantation rate ranged from 7.6% to 31% in DCD-LT 
compared to 2.5%-12% in DBD-LT[20,29,34,36,51,67-69,71,72,91,92,106]. 
DCD livers exhibited a 2.1 times greater risk of  graft fail-
ure, a 2.5 times greater risk of  re-listing, and a 3.2 times 
greater risk of  re-transplantation compared with DBD 
livers[36]. The majority of  re-listing and re-transplantation 
in the DCD group were a consequence of  biliary com-
plications, especially ischemic cholangiography, but not 
due to an increased incidence of  PNF, HAT or technical 
complications[36,69]. Particularly DCD livers had a tempo-
rally different failure pattern within the first year post-
transplant that limited access to re-transplantation[36,69]: 
graft failure was more likely to occur within the first 180 
d (18.1% vs 11.7%[67], 10.2% vs 2.5%[72] and 20.5% vs 
11.5%[69] of  DCD and DBD grafts failed within 60, 90 
and 180 d, respectively); at re-transplantation, DCD re-
cipients waited longer and received higher risk allografts; 
and more DCD recipients remained waiting for re-
transplantation with fewer removed for death, clinical de-
terioration, or improvement. Re-transplantation arouses 
controversy on medical, economic, and ethical grounds: 
patient and graft survival rates after a second LT are 
inferior to those after initial grafting, the procedure is 
more expensive and in the context of  organ shortage, 
re-transplantation inevitably denies organs to first-time 
recipients[129]. 
Utilization of  DCD allografts for re-transplantation 
was rare (2.5% of  initial DCD vs 3.1% of  initial DBD) 
and outcomes from each group were comparable[69]. 
The general practice is to avoid re-transplantation with a 
DCD graft[36]. The use of  DCD donors in the setting of  
re-transplantation resulted in an increased risk of  recipi-
ent death (hazard ratio = 2.1, 95% CI: 1.2-3.6)[129].  
Acute rejection  
The acute rejection rate did not differ significantly be-
tween DCD- and DBD-LT in most studies (1.9%-29% 
vs 0.6%-34%)[20,72,87,89,104]. Foley et al[91] reported a one-year 
rejection rate of  61% in the DCD group similar to that in 
the DBD group (56%). There were little data looking at 
the impact of  DCD source on the risk of  acute rejection. 
 
EXPERIMENTAL STRATEGIES TO 
IMPROVE DCD-LT OUTCOMES 
The progressively increased DCD liver procurement to 
solve the shortage of  DBD organs and to alleviate the 
waiting-list mortality has raised many challenges to the 
transplant community and transplant policy makers[110]. 
A lot of  experimental researches have been performed 
over the past decade, intervening in both donors and 
recipients at different phases of  the transplantation pro-
cess, at the aim of  tackling some of  these challenges and 
providing a deep insight into IRI mechanisms. 
Donor pre-treatment 
Various cyto-protective substances have been successful-
ly administered into the donor prior to cardiac arrest for 
prevention of  liver microcirculatory disturbance. Micro-
circulatory disturbance was the main obstacle to success-
ful DCD-LT, which was due to four major mechanisms: 
deterioration of  sinusoidal endothelial cells (SEC) caused 
by activated Kupffer cells, sinusoidal narrowing caused 
by some vasoconstrictors and swollen hepatocytes, leu-
kocyte and platelet adhesion, and hyper-coagulability[130]. 
Up to now, only Heparin and phentolamin (an anticoagu-
lative substance and alpha-adrenergic antagonist) are 
allowed in clinical DCD organ procurement[131], other 
substances remain in animal models. Tacrolimus, besides 
Le Dinh H et al . DCD liver transplantation
4500 September 7, 2012|Volume 18|Issue 33|WJG|www.wjgnet.com
its powerful immunosuppression, enabled to prevent 
liver normothermic IRI by multiple mechanisms[132]. Mil-
rinone, a type 3 phosphodiesterase inhibitor, attenuated 
graft injury caused by warm and cold ischemia via an 
increase in intracellular cAMP levels, protection of  SEC, 
relaxation of  hepatic stellate cells, inhibition of  platelet 
aggregation and anti-inflammatory effect[133]. Lazaroids, 
an antioxidant designed to inhibit iron-dependent lipid 
peroxidation, ameliorated SEC viability via antioxidant 
effects and membrane stabilization[134]. N-acetylcystein has 
a direct effect on oxygen free radicals, but its usage had 
no effect in both graft viability and lipid peroxidation[135]. 
Animal studies clearly showed the concept of  phar-
macological modulation of  organ donors before pro-
curement is feasible to improve the viability of  marginal 
grafts. Nevertheless there are no definitive recommen-
dations for the use of  these drugs. Application of  this 
method to clinical LT would require management of  
some practical problems and possible ethical conflicts[136]. 
Organ preservation 
Preservation of  DCD livers by hypothermic machine 
perfusion (HMP) was shown superior to static cold stor-
age (SCS) in many experimental studies[137,138]. 
Nonetheless a putative drawback of  HMP for liv-
ers is to induce alterations at the vascular endothelial 
site, especially if  HMP was performed for a long time 
or under suboptimal conditions[139]. Endoplasmic stress 
activation promoted cellular apoptosis via activation of  
caspase-12[140,141]. The efficiency of  HMP was markedly 
increased by oxygenation of  the perfusate[142]. The con-
cern that high oxygenation might favor the generation 
of  oxygen free radicals, which in turn could impair tissue 
integrity, was not justified. Several investigators could 
demonstrate the beneficial effect of  oxygenated HMP in 
reducing the liver expression of  pro-inflammatory cyto-
kines (TNF-α, IL-8), adhesion molecules (ICAM-1) and 
major histocompatibility complex class Ⅱ antigens[143-145]. 
This benefit will likely be more pronounced in marginal 
grafts such as elderly, steatotic and DCD livers[144]. Cyto-
protective agents can be added into the machine perfu-
sion (MP) solution to ameliorate the efficiency of  HMP 
organ preservation[146].  
The positive effects of  HMP on warm-ischemically 
pre-damaged livers were observed even after a brief  pe-
riod of  MP, before (pre-conditioning) or after SCS (post-
conditioning)[143,147] and therefore it was not necessary to 
require MP over a full preservation period and helped 
avoid side-effects of  HMP on vascular endothelium[141]. 
The use of  HMP as the initial method for organ preser-
vation followed by secondary SCS during transportation 
combined the advantage of  aerobic resuscitation (i.e., 
restitution of  cellular homeostasis) with an ease of  SCS 
for later surveillance and transportation[141]. Manekeller 
showed a post-conditioning of  1 h after SCS can ame-
liorate the viability of  marginal livers. The extension or 
abbreviation of  post-conditioning time seems to have no 
further beneficial effects[148]. 
Schön et al[66] reported advantages of  normothermic 
machine perfusion (NMP) over SCS in pig DCD-LT 
models. Livers subjected to 1 h of  WI and then cold-
stored for 4-24 h were rendered completely nonviable 
while such livers under 4-24 h of  oxygenated NMP 
recovered function to a viable level[149]. Due to the com-
plexity of  the logistics of  clinical multi-organ recovery 
and of  the NMP device, a period of  cold preservation 
prior to warm perfusion of  the liver is unescapable. A 
brief  period of  cold preservation (1 h) prior to NMP 
could maintain the synthetic and metabolic function but 
resulted in significant hepatocellular damage, sinusoidal 
endothelial cell dysfunction and Kupffer cell injury[150]. 
Once this duration was prolonged to 4 h, NMP com-
pletely failed to resuscitate porcine livers[151]. Normother-
mically perfusing DCD livers throughout the preserva-
tion period not only replenished cellular substrate, ame-
liorating the ischemic injury, but also provided a clear 
assessment of  liver function and therefore could permit 
the use of  severely injured organs with reassurance of  
function[149,152]. 
Despite the aforementioned benefits of  MP over 
SCS in liver preservation, only SCS is clinically approved 
up to now, MP is still in the pre-clinical stage and early 
clinical studies[153]. Tojimbara showed the impact of  vis-
cosity and temperature of  initial flushing solutions on 
graft function. A low viscosity flushing solution was as-
sociated with lower vascular resistance, whereas a warm 
flush solution prevented cold-induced vasospasm and 
therefore improved the washout effect of  the microcir-
culation[154]. HTK solution possessing a low viscosity and 
low potassium is more preferable in the DCD setting. 
The role of  aeration of  the cold-stored liver was also 
clarified. Oxygen provided either by surface diffusion 
(surface oxygenation) or intravascular diffusion (oxygen 
persufflation) helps improve the energy status of  organs 
thus leading to earlier recovery. Surface oxygenation 
was not in use any more due to complicated technique, 
limited efficiency and risk of  oxygen intoxication[155]. Ve-
nous systemic oxygen persufflation (VSOP) was shown 
to improve organ viability during hypothermic storage 
of  the grafts and to be a feasible means for recondition-
ing of  warm-ischemically pre-injured livers from DCD 
donors[155-158]. Experimentally even a short period of  
VSOP prior to long-term preservation of  the liver by 
SCS may be sufficient for a relevant improvement of  liv-
er integrity upon reperfusion[159]. Gaseous persufflation 
with carbon monoxide was also tested in a DCD-LT rat 
model with enhanced liver graft viability[160]. However no 
additive or synergistic effect was noted when livers were 
persufflated with a mixture of  gaseous oxygen and car-
bon monoxide[161].
Pharmaceutical interventions during SCS aimed at 
conditioning marginal organs also increasingly gained at-
tention. Different cyto-protective drugs have been added 
into the flush and/or preservation solution, like vaso-
dilators (phentolamin, epoprosterol, dopamine)[162,163], 
anti-coagulants (heparin), fibrinolytic agents (strepto-
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kinase)[164], antioxydants (superoxide dismutase, edara-
vone)[165,166], antibiotics, hormones (glucagon, growth 
factors)[167]. In the DCD setting, vasodilators, anti-coag-
ulants, thrombolytic agents and antibiotics seem particu-
larly necessary because the organs tend to develop vaso-
spasm, thrombus formation in the microcirculation and 
the risk of  colonic bacterial contamination secondary to 
translocation of  organisms during the WI period[168,169].  
Viability testing 
Due to serious consequences of  transplanting a DCD 
liver with potentially severe IRI (PNF, re-transplantation 
or even recipient death), it would be ideal if  the viability 
of  such livers could be predicted prior to rather than after 
transplantation. WIT is not always exactly known and 
thus cannot be a reliable parameter. Light microscopic 
examination of  biopsy specimens was unable to 
uniformly predict liver function after transplantation[170]. 
Monbaliu showed the extent of  parenchyma vacuolation 
predicted pig liver graft viability before LT[171]. Muiesan et 
al[70] applied the mechanical digestion of  liver biopsies with 
collagenase and assessed the viability of  hepatocytes by 
trypan blue exclusion method. However, the test was not 
helpful and the decision as to whether to use the liver was 
generally made on gross appearance, ease of  perfusion, 
degree of  steatosis and donor characteristics[172].
Another approach is to evaluate the vascular resis-
tance and enzyme release in the perfusate of  HMP livers. 
Resistance index of  the portal vein and hepatic artery 
showed no utility[173]. Biomarkers of  liver cell damage, 
like transaminases, lactate dehydrogenase and liver fatty 
acid binding protein, correlated well with WI dura-
tion and concomitant hepatocyte damage in pig DCD-
LT models[174]. Possible other parameters are the ATP 
content and redox active iron status of  the liver during 
HMP[175]. During NMP, the assessment of  liver viability 
may be easier because the liver is in a normal metabolic 
state. Bile production was a good viability indicator be-
sides the measurement of  other liver functions (detoxifi-
cation, metabolism or synthesis)[176]. Recently Liu et al[177] 
has tested the utility of  magnetic resonance imaging and 
proton magnetic resonance spectroscopy to evaluate WI 
livers without success.  
Recipient treatment  
Pharmaceutical strategies aimed at modulating IRI 
mechanisms were also applied successfully in animal 
recipients and generally did not impose ethical problems 
as donor pre-treatment. Such protocols without donor 
pretreatment will be favorable in clinical application. Most 
studies tested a single agent for a specific target of  the IRI 
process. A multi-factorial approach acting on different 
pathways of  the IRI process have been advocated and 
remarkably ameliorated transplant outcomes[162].  
PERSPECTIVES 
The future of  DCD-LT is promising. Concerted efforts 
should concentrate on the identification of  suitable 
donors (probably Maastricht category Ⅲ DCD donors), 
better donor and recipient matching (high risk donors to 
low risk recipients), use of  advanced organ preservation 
techniques (oxygenated HMP and NMP, VSOP), and 
pharmacological modulation (probably a multi-factorial 
biologic modulation strategy) so that liver procurement 
and transplantation from DCD donors could be widely 
expanded and attain equivalent results as DBD-LT.  
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